dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:21:17Z
dc.date.accessioned2022-10-05T17:55:57Z
dc.date.available2014-05-27T11:21:17Z
dc.date.available2022-10-05T17:55:57Z
dc.date.created2014-05-27T11:21:17Z
dc.date.issued2005-03-01
dc.identifierJornal de Pediatria, v. 81, n. 2, p. 175-178, 2005.
dc.identifier0021-7557
dc.identifierhttp://hdl.handle.net/11449/68160
dc.identifier10.2223/1325
dc.identifier2-s2.0-28244457913
dc.identifier2-s2.0-28244457913.pdf
dc.identifier2559637400719543
dc.identifier0246391303241376
dc.identifier9919910234219937
dc.identifier1197755531108177
dc.identifier0000-0002-0648-876X
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3917735
dc.description.abstractObjective: To report on the use of sildenafil for pulmonary hypertension treatment of a newborn patient after cardiac surgery. Description: A female, full term newborn infant with diagnosis of double outlet right ventricle, pulmonary hypoplasia and subaortic ventricular septal defect, was submitted to Blalock surgery in the first week of life. In postoperative the newborn had pulmonary hypertension and persistent hypoxia, without response to nitric oxide, but with improved oxygenation after continuous intravenous infusion of prostaglandin E1. After several failed attempts to discontinue prostaglandin E1, oral sildenafil was used. There was a decrease in pulmonary vascular resistance with consequent oxygenation improvement and 48 hours later it was possible to discontinue prostaglandin E1 infusion. Comments: Sildenafil can be an alternative therapy for pulmonary hypertension, especially when there is no response to conventional therapy. Copyright © 2005 by Sociedade Brasileira de Pediatria.
dc.languageeng
dc.relationJornal de Pediatria
dc.relation1.690
dc.relation0,704
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectProstaglandin
dc.subjectPulmonary hypertension
dc.subjectSildenafil
dc.subjectnitric oxide
dc.subjectprostaglandin E1
dc.subjectsildenafil
dc.subjectphosphodiesterase inhibitor
dc.subjectpiperazine derivative
dc.subjectBlalock Taussig anastomosis
dc.subjectcardiovascular parameters
dc.subjectcase report
dc.subjectdiagnostic procedure
dc.subjectdrug dose regimen
dc.subjectdrug mechanism
dc.subjectfemale
dc.subjectheart right ventricle double outlet
dc.subjectheart surgery
dc.subjectheart ventricle septum defect
dc.subjecthuman
dc.subjecthypoxia
dc.subjectlung hypoplasia
dc.subjectnewborn
dc.subjectoxygenation
dc.subjectpulmonary hypertension
dc.subjectpostoperative period
dc.subjectCardiac Surgical Procedures
dc.subjectFemale
dc.subjectHumans
dc.subjectHypertension, Pulmonary
dc.subjectInfant, Newborn
dc.subjectPhosphodiesterase Inhibitors
dc.subjectPiperazines
dc.subjectPostoperative Period
dc.titleSildenafil for pulmonary hypertension treatment after cardiac surgery
dc.typeArtigo


Este ítem pertenece a la siguiente institución